These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The specificity of the malarial VAR2CSA protein for chondroitin sulfate depends on 4-O-sulfation and ligand accessibility. Spliid CB; Toledo AG; Sanderson P; Mao Y; Gatto F; Gustavsson T; Choudhary S; Saldanha AL; Vogelsang RP; Gögenur I; Theander TG; Leach FE; Amster IJ; Esko JD; Salanti A; Clausen TM J Biol Chem; 2021 Dec; 297(6):101391. PubMed ID: 34762909 [TBL] [Abstract][Full Text] [Related]
7. Oncofetal Chondroitin Sulfate: A Putative Therapeutic Target in Adult and Pediatric Solid Tumors. Khazamipour N; Al-Nakouzi N; Oo HZ; Ørum-Madsen M; Steino A; Sorensen PH; Daugaard M Cells; 2020 Mar; 9(4):. PubMed ID: 32231047 [TBL] [Abstract][Full Text] [Related]
8. Novel single-chain antibody GD3A10 defines a chondroitin sulfate biomarker for ovarian cancer. Vallen MJ; van Tilborg AA; Tesselaar MH; ten Dam GB; Bulten J; van Kuppevelt TH; Massuger LF Biomark Med; 2014; 8(5):699-711. PubMed ID: 25123038 [TBL] [Abstract][Full Text] [Related]
9. Antibody GD3G7 selected against embryonic glycosaminoglycans defines chondroitin sulfate-E domains highly up-regulated in ovarian cancer and involved in vascular endothelial growth factor binding. ten Dam GB; van de Westerlo EM; Purushothaman A; Stan RV; Bulten J; Sweep FC; Massuger LF; Sugahara K; van Kuppevelt TH Am J Pathol; 2007 Oct; 171(4):1324-33. PubMed ID: 17717144 [TBL] [Abstract][Full Text] [Related]
10. Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4. Wang X; Katayama A; Wang Y; Yu L; Favoino E; Sakakura K; Favole A; Tsuchikawa T; Silver S; Watkins SC; Kageshita T; Ferrone S Cancer Res; 2011 Dec; 71(24):7410-22. PubMed ID: 22021902 [TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of highly sulfated chondroitin sulfates in ovarian cancer defined by the single chain antibody GD3A11. van der Steen SC; van Tilborg AA; Vallen MJ; Bulten J; van Kuppevelt TH; Massuger LF Gynecol Oncol; 2016 Mar; 140(3):527-36. PubMed ID: 26731725 [TBL] [Abstract][Full Text] [Related]
12. Establishment and validation of a plasma oncofetal chondroitin sulfated proteoglycan for pan-cancer detection. Zhang PF; Wu ZY; Zhang WB; He YQ; Chen K; Wang TM; Li H; Zheng H; Li DH; Yang DW; Zhou T; Deng CM; Liao Y; Xue WQ; Cao LJ; Li XZ; Zhang JB; Dong SQ; Wang F; Zheng MQ; Zhang WL; Mu J; Jia WH Nat Commun; 2023 Feb; 14(1):645. PubMed ID: 36746966 [TBL] [Abstract][Full Text] [Related]
13. Malaria Biomimetic for Tumor Targeted Drug Delivery. Pihl J; Clausen TM; Zhou J; Krishnan N; Ørum-Madsen MS; Gustavsson T; Dagil R; Daugaard M; Choudhary S; Foged C; Esko JD; Zhang L; Fang RH; Salanti A ACS Nano; 2023 Jul; 17(14):13500-13509. PubMed ID: 37435892 [TBL] [Abstract][Full Text] [Related]
14. Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effector Bispecific Design. Lee NK; Su Y; Bidlingmaier S; Liu B Mol Cancer Ther; 2019 Jun; 18(6):1092-1103. PubMed ID: 30962321 [TBL] [Abstract][Full Text] [Related]
15. An Antibody-Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies. Asundi J; Crocker L; Tremayne J; Chang P; Sakanaka C; Tanguay J; Spencer S; Chalasani S; Luis E; Gascoigne K; Desai R; Raja R; Friedman BA; Haverty PM; Polakis P; Firestein R Clin Cancer Res; 2015 Jul; 21(14):3252-62. PubMed ID: 25862760 [TBL] [Abstract][Full Text] [Related]
16. Novel Antibody Drug Conjugates Targeting Tumor-Associated Receptor Tyrosine Kinase ROR2 by Functional Screening of Fully Human Antibody Libraries Using Transpo-mAb Display on Progenitor B Cells. Hellmann I; Waldmeier L; Bannwarth-Escher MC; Maslova K; Wolter FI; Grawunder U; Beerli RR Front Immunol; 2018; 9():2490. PubMed ID: 30450096 [TBL] [Abstract][Full Text] [Related]
17. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Sharkey RM; McBride WJ; Karacay H; Chang K; Griffiths GL; Hansen HJ; Goldenberg DM Cancer Res; 2003 Jan; 63(2):354-63. PubMed ID: 12543788 [TBL] [Abstract][Full Text] [Related]
18. A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface. Tang Z; Feng M; Gao W; Phung Y; Chen W; Chaudhary A; St Croix B; Qian M; Dimitrov DS; Ho M Mol Cancer Ther; 2013 Apr; 12(4):416-26. PubMed ID: 23371858 [TBL] [Abstract][Full Text] [Related]
19. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22. DiJoseph JF; Popplewell A; Tickle S; Ladyman H; Lawson A; Kunz A; Khandke K; Armellino DC; Boghaert ER; Hamann P; Zinkewich-Peotti K; Stephens S; Weir N; Damle NK Cancer Immunol Immunother; 2005 Jan; 54(1):11-24. PubMed ID: 15693135 [TBL] [Abstract][Full Text] [Related]
20. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Loo D; Alderson RF; Chen FZ; Huang L; Zhang W; Gorlatov S; Burke S; Ciccarone V; Li H; Yang Y; Son T; Chen Y; Easton AN; Li JC; Rillema JR; Licea M; Fieger C; Liang TW; Mather JP; Koenig S; Stewart SJ; Johnson S; Bonvini E; Moore PA Clin Cancer Res; 2012 Jul; 18(14):3834-45. PubMed ID: 22615450 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]